 In a still-fresh press release, Clovis Oncology NASDAQ: CLVS just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to submit a supplemental New Drug Application NDA to the Food and Drug Administration FDA for a specific subgroup of prostate cancer patients and intends to discuss NDA submission for a broader patient population with the FDA. 